Patents Assigned to Merus N.V.
-
Publication number: 20200319181Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Applicant: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 10752929Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: May 20, 2019Date of Patent: August 25, 2020Assignee: Merus N.V.Inventors: Cornelis Adriaan De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Publication number: 20200247908Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.Type: ApplicationFiled: April 17, 2020Publication date: August 6, 2020Applicant: Merus N.V.Inventors: Mark THROSBY, Ton LOGTENBERG, John DE KRUIF
-
Patent number: 10670599Abstract: The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.Type: GrantFiled: August 21, 2017Date of Patent: June 2, 2020Assignee: Merus N.V.Inventors: Hendricus Renerus Jacobus Mattheus Hoogenboom, Ton Logtenberg
-
Patent number: 10647781Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.Type: GrantFiled: November 22, 2017Date of Patent: May 12, 2020Assignee: Merus N.V.Inventors: Mark Throsby, Ton Logtenberg, John De Kruif
-
Patent number: 10605808Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 27, 2016Date of Patent: March 31, 2020Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. Dekruif, Erwin Houtzager
-
Publication number: 20190352393Abstract: Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.Type: ApplicationFiled: April 19, 2019Publication date: November 21, 2019Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo, Ton Logtenberg
-
Patent number: 10358492Abstract: Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.Type: GrantFiled: September 27, 2013Date of Patent: July 23, 2019Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo, Ton Logtenberg
-
Publication number: 20190211100Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSs with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: ApplicationFiled: January 11, 2019Publication date: July 11, 2019Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO
-
Patent number: 10337045Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: April 25, 2017Date of Patent: July 2, 2019Assignee: Merus N.V.Inventors: Cornelis Adriaan De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 10329596Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: May 16, 2016Date of Patent: June 25, 2019Assignee: Merus N.V.Inventors: Cornelis Adriaan De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 10266593Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS CFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2 RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: GrantFiled: February 5, 2018Date of Patent: April 23, 2019Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo
-
Publication number: 20180237523Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS CFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2 RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: ApplicationFiled: February 5, 2018Publication date: August 23, 2018Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko Van Loo
-
Publication number: 20180179300Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.Type: ApplicationFiled: November 22, 2017Publication date: June 28, 2018Applicant: Merus N.V.Inventors: Mark THROSBY, Ton LOGTENBERG, John DE KRUIF
-
Publication number: 20180142003Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 9, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142002Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 5, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142005Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142006Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142004Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 11, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Rui Daniel PINTO, Erwin HOUTZAGER
-
Patent number: RE47770Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: May 18, 2016Date of Patent: December 17, 2019Assignee: Merus N.V.Inventors: Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout